Clinical Trial Update: Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bone-marrow derived mesenchymal stromal cells for new onset chronic lung allograft dysfunction has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Allograft Dysfunction

Drugs mentioned

• Bone-marrow derived mesenchymal stromal cells (bone marrow-derived mesenchymal stromal cells)

Snippet

Sponsor: The University of Queensland | Conditions: Chronic Lung Allograft Dysfunction (CLAD) | Phase 2 | Status: COMPLETED